---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-22-000086"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2022-09-27T23:59:59+00:00"
generated_at: "2026-06-23T07:18:55.466558+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics extends cash runway to Q1 2024, prioritizes key pipeline programs

## Summary
- Cash runway extended to Q1 2024; deferring noncritical R&D and reducing overhead.
- ONA-XR ELONA Phase 1b/2 trial with elacestrant for ER+/PR+/HER2- mBCa starts Q4 2022; data Q4 2023.
- CLDN6xCD3 BsMAb candidate nomination Q4 2022; IND submission planned Q1 2024.
- Preliminary data from ISTs: granulosa cell/endometrial cancer Nov 2022; breast cancer Dec 2022.

## SEC filing metadata
- accession: 0001842952-22-000086
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2022-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295222000086/0001842952-22-000086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295222000086/cntx-20220927.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-22-000086
- JSON: https://secwatch.observer/filing/0001842952-22-000086.json
- Plain text: https://secwatch.observer/filing/0001842952-22-000086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.